OncoMatch/Clinical Trials/NCT06248515
A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
Is NCT06248515 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Sacituzumab govitecan-hziy for thymoma.
Treatment: Sacituzumab govitecan-hziy — The goal of this clinical trial is to study the effect of sacituzumab govitecan-hziy in adult patients with advanced thymoma and thymic carcinoma after progressing on at least one prior line of therapy. The main question it aims to answer is: • What is the overall response rate (ORR) in patients with advanced thymoma and thymic carcinoma? Participants will: * receive a fixed dose of 10 mg/kg given intravenously, once weekly on Days 1 and 8 of continuous 21-day treatment cycles until disease progression or unacceptable toxicity * have regular blood tests, scans, and examinations to monitor their health. * have blood and a biopsy of their tumor for research purposes.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Disease stage
Metastatic disease required
Patients with histologically confirmed advanced thymoma or thymic carcinoma; Measurable disease per RECIST v1.1
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy
Lab requirements
Blood counts
ANC 3E/= 1.5 x 10^9/L (1500/uL) without filgrastim support; Platelet count 3E/= 100 x 10^9/L (100,000/uL) without transfusion; Hemoglobin 3E/= 80 g/L (8 g/dL), may be transfused to meet criterion
Kidney function
Creatinine clearance 3E/= 30 mL/min (Cockcroft-Gault)
Liver function
AST, ALT, ALP 3C=/= 2.5 x ULN (exceptions: AST/ALT 3C=/= 5 x ULN with liver metastases; ALP 3C=/= 5 x ULN with liver or bone metastases); serum bilirubin 3C=/= 1.5 x ULN (or 3C=/= 3 x ULN with Gilbert disease)
Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained within 14 days prior to initiation of study treatment: * Absolute neutrophil count (ANC) 3E/= 1.5 x 10^9/L (1500/uL) without filgrastim support * Platelet count 3E/= 100 x 10^9/L (100,000/uL) without transfusion * Hemoglobin (Hgb) 3E/= 80 g/L (8 g/dL). Patients may be transfused to meet this criterion. * Aspartate aminotransferase (AST), alanine transaminase (ALT), and alkaline phosphatase (ALP) 3C=/= 2.5 x upper limit of normal (ULN), with the following exceptions: * Patients with documented liver metastases: AST and ALT 3C=/= 5 x ULN * Patients with documented liver or bone metastases: ALP 3C=/= 5 x ULN Serum bilirubin 3C=/= 1.5 x ULN with the following exception: patients with known Gilbert disease: serum bilirubin 3C=/= 3 x ULN * Creatinine clearance 3E/= 30 mL/min (calculated using the Cockcroft-Gault formula, see Appendix 2) * For patients not receiving therapeutic anticoagulation: INR and aPTT 3C=/= 1.5 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford Cancer Institute · Palo Alto, California
- Lombardi Comprehensive Cancer Center, Georgetown University · Washington D.C., District of Columbia
- University of Chicago Medical Center · Chicago, Illinois
- John Theurer Cancer Center at Hackensack University Medical Center · Hackensack, New Jersey
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06248515 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received systemic therapy.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify